Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion type Assertion NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_head.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion description "[Patients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion evidence source_evidence_literature NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion SIO_000772 18765546 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion wasDerivedFrom befree-20140225 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.
- NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_assertion wasGeneratedBy ECO_0000203 NP161755.RAwGxnwKVC-DkwzZB4GUc__gRuA9p3_OToax-Cf7jJv3o130_provenance.